2015年以降の研究業績

英文原著論文

  1. 1.Mine H, Sugimoto K, Kobayashi M, Takagi H, Okabe N, Muto S, Kobayashi Y, Hashimoto Y, Suzuki H, Chiba H. Abnormal phosphorylation of human LRH1 at Ser510 predicts poor prognosis and promotes cell viability in lung squamous cell carcinoma. BMC Cancer. 2025
  2. 2.Kobayashi Y, Sugimoto K, Ishibashi M, Kobayashi M, Igari S, Kitamura S, Yamamoto T, Hashimoto Y, Chiba H. IgSF11-RAP1 signaling promotes cell migration and invasion of cutaneous melanoma. Cell Commun Signal. 2025
  3. 3.Saito AC, Higashi T, Chiba H. Protocol for establishing knockout cell clones by deletion of a large gene fragment using CRISPR-Cas9 with multiple guide RNAs. STAR Protoc. 2024
  4. 4.Onagi A, Sugimoto K, Kobayashi M, Sato Y, Kobayashi Y, Yaginuma K, Meguro S, Hoshi S, Hata J, Hashimoto Y, Kojima Y, Chiba H. Extrajunctional CLDN10 cooperates with LAT1 and accelerates clear cell renal cell carcinoma progression. Cell Commun Signal. 2024
  5. 5.Higashi T, Saito AC, Chiba H. Damage control of epithelial barrier function in dynamic environments. Eur J Cell Biol. 2024
  6. 6.Higashi AY, Saito AC, Higashi T, Furuse K, Furuse M, Chiba H, Kazama JJ. Bicellular Localization of Tricellular Junctional Protein Angulin-3/ILDR2 Allows Detection of Podocyte Injury. Am J Pathol. 2024
  7. 7.Saito AC, Higashi T, Chiba H. Tight-junction strand networks and tightness of the epithelial barrier. Microscopy (Oxf). 2023
  8. 8.Nishimagi A, Kobayashi M, Sugimoto K, Kofunato Y, Sato N, Haga J, Ishigame T, Kimura T, Kenjo A, Kobayashi Y, Hashimoto Y, Marubashi S, Chiba H. Aberrant phosphorylation of human LRH1 at serine 510 is predictable of hepatocellular carcinoma recurrence. Clin Exp Med. 2023.
  9. 9.Murakami-Nishimagi Y, Sugimoto K, Kobayashi M, Tachibana K, Kojima M, Okano M, Hashimoto Y, Saji S, Ohtake T, Chiba H. Claudin-4-adhesion signaling drives breast cancer metabolism and progression via liver X receptor β. Breast Cancer Res. 2023
  10. 10.Miyakawa R, Kobayashi M, Sugimoto K, Endo Y, Kojima M, Kobayashi Y, Furukawa S, Honda T, Watanabe T, Asano S, Soeda S, Hashimoto Y, Fujimori K, Chiba H. SPON1 is an independent prognostic biomarker for ovarian cancer. J Ovarian Res. 2023
  11. 11.Higashi T, Saito AC, Fukazawa Y, Furuse M, Higashi AY, Ono M, Chiba H. EpCAM proteolysis and release of complexed claudin-7 repair and maintain the tight junction barrier. J Cell Biol, 2023.
  12. 12.Endo Y, Sugimoto K, Kobayashi M, Kobayashi Y, Kojima M, Furukawa S, Soeda S, Watanabe T, Higashi AY, Higashi T, Hashimoto Y, Fujimori K, Chiba H. Claudin 9 is a novel prognostic biomarker for endometrial cancer. Int J Oncol. 2022
  13. 13.Saito AC, Endo C, Fukazawa Y, Higashi T, Chiba H. Effects of TAMP family on the tight junction strand network and barrier function in epithelial cells. Ann N Y Acad Sci. 2022
  14. 14.Kashiwagi K, Sato-Yazawa H, Ishii J, Kohno K, Tatsuta I, Miyazawa T, Takagi M, Chiba H, Yazawa T. LXRβ Activation Inhibits the Proliferation of Small-cell Lung Cancer Cells by Depleting Cellular Cholesterol. Anticancer Res. 2022
  15. 15.Ito Y, Takasawa A, Takasawa K, Murakami T, Akimoto T, Kyuno D, Kawata Y, Shano K, Kirisawa K, Ota M, Aoyama T, Murata M, Sugimoto K, Chiba H, Saito T, Osanai M. Aberrant expression of claudin-6 contributes to malignant potentials and drug resistance of cervical adenocarcinoma. Cancer Sci. 2022
  16. 16.Mochizuki K, Kobayashi S, Takahashi N, Sugimoto K, Sano H, Ohara Y, Mineishi S, Zhang Y, Kikta A. Alloantigen-activated (AAA) CD4+ T cells reinvigorate host endogenous T cell immunity to eliminate pre-established tumors in mice.JExp Clin Cancer Res. 2021
  17. 17.Higashi AY, Higashi T, Furuse K, Ozeki K, Furuse M, Chiba H. Claudin-9 constitutes tight junctions of folliculo-stellate cells in the anterior pituitary gland. Sci Rep. 2021
  18. 18.Saito AC, Higashi T, Fukazawa Y, Otani T, Tauchi M, Higashi AY, Furuse M, Chiba H. Occludin and tricellulin facilitate formation of anastomosing tight-junction strand network to improve barrier function. Mol Biol Cell. 2021
  19. 19.Chiba H, Ichikawa-Tomikawa N, Imura T, Sugimoto K. The region-selective regulation of endothelial claudin-5 expression and signaling in brain health and disorders. J Cell Physiol. 2021
  20. 20.Sugimoto K, Chiba H. The claudin-transcription factor signaling pathway. Tissue Barriers. 2021
  21. 21.Kojima M, Sugimoto K, Kobayashi M, Ichikawa-Tomikawa N, Kashiwagi K, Watanabe T, Soeda S, Fujimori K, Chiba H. Aberrant Claudin-6-Adhesion Signaling Promotes Endometrial Cancer Progression via Estrogen Receptor α. Mol Cancer Res. 2021
  22. 22.Watanabe M, Higashi T, Ozeki K, Higashi AY, Sugimoto K, Mine H, Takagi H, Ozaki Y, Muto S, Okabe N, Matsumura Y, Hasegawa T, Shio Y, Suzuki H, Chiba H. CLDN15 is a novel diagnostic marker for malignant pleural mesothelioma. Sci Rep. 2021
  23. 23.Yamashita R, Tanaka M, Chiba H, Sugimoto K. Bacterial Myocarditis in a Patient with Cancer. JMA J. 2021
  24. 24.Rahman A, Kobayashi M, Sugimoto K, Endo Y, Kojima M, Furukawa S, Watanabe T, Soeda S, Hashimoto Y, Fujimori K, Chiba H. Reduced Claudin-12 Expression Predicts Poor Prognosis in Cervical Cancer. Int J Mol Sci. 2021
  25. 25.Yamazaki M, Sugimoto K, Mabuchi Y, Yamashita R, Ichikawa-Tomikawa N, Kaneko T, Akazawa C, Hasegawa H, Imura T, Chiba H. Soluble JAM-C Ectodomain Serves as the Niche for Adipose-Derived Stromal/Stem Cells. Biomedicines. 2021
  26. 26.Sugimoto K, Ichikawa-Tomikawa N, Nishiura K, Kunii Y, Sano Y, Shimizu F, Kakita A, Kanda T, Imura T, Chiba H. Serotonin/5-HT1A Signaling in the Neurovascular Unit Regulates Endothelial CLDN5 Expression. Int J Mol Sci. 2020
  27. 27.Kojima M, Sugimoto K, Tanaka M, Endo Y, Kato H, Honda T, Furukawa S, Nishiyama H, Watanabe T, Soeda S, Fujimori K, Chiba H. Prognostic Significance of Aberrant Claudin-6 Expression in Endometrial Cancer. Cancers. 2020
  28. 28.Higashi T, Chiba H. Molecular organization, regulation and function of tricellular junctions. Biochim Biophys Acta Biomembr. 2020
  29. 29.Sugimoto K, Ichikawa-Tomikawa N, Kashiwagi K, Endo C, Tanaka S, Sawada N, Watabe T, Higashi T, Chiba H. Cell adhesion signals regulate the nuclear receptor activity. Proc Natl Acad Sci USA. 2019
  30. 30.Sugimoto K, Tanaka M, Chiba H, Myocardial Rupture Due to Metastasis of Urothelial Carcinoma. Circ J. 2019
  31. 31.Okai K, Ichikawa-Tomikawa N, Saito AC, Watabe T, Sugimoto K, Fujita D, Ono C, Fukuhara T, Matsuura Y, Ohira H, Chiba H.A novel occludin-targeting monoclonal antibody prevents hepatitis C virus infection in vitro. Oncotarget. 2018
  32. 32.Kashiwagi K, Yanagida M, Matsui D, Tanaka M, Sugimoto K, Chen H, Ichikawa-Tomikawa N, S. Marubashi, H. Suzuki, H. Chiba. Expression of liver X receptors in normal and refractory carcinoma tissues of the human lung and pancreas.Histol Histopathol. 2017
  33. 33.Nishiura K, Ichikawa-Tomikawa N, Sugimoto K, Kunii Y, Kashiwagi K, Tanaka M, Yokoyama Y, Hino M, Sugimot T, Yabe H, Takahashi H, Kakita A, Imura T, Chiba H. PKA activation and endothelial claudin-5 breakdown in the schizophrenic prefrontal cortex.Oncotarget. 2017
  34. 34.Kaneko T, Kanno C, Ichikawa-Tomikawa N, Kashiwagi K, Yaginuma N, Ohkoshi C, Tanaka M, Sugino T, Imura T, Hasegawa H, Chiba H. Liver X receptor reduces proliferation of human oral cancer cells by promoting cholesterol efflux via up-regulation of ABCA1 expression.Oncotarget. 2015
  35. 35.Tanaka M, Ichikawa-Tomikawa N, Shishito N, Nishiura K, Miura T, Hozumi A, Chiba H, Yoshida S, Ohtake T, Sugino T. Co-expression of S100A14 and S100A16 correlates with a poor prognosis in human breast cancer and promotes cancer cell invasion.BMC Cancer. 2015

総説論文

症例報告

受賞

研究費

2000年以降の研究業績

ページの先頭へ戻る